What is the recommended dosing and management of Brilinta (ticagrelor) for a patient with acute coronary syndrome or a history of percutaneous coronary intervention (PCI) who requires antiplatelet therapy?

Brilinta (Ticagrelor) Dosing and Management for ACS/PCI

For patients with acute coronary syndrome or post-PCI, initiate Brilinta (ticagrelor) 180 mg loading dose followed by 90 mg twice daily, combined with low-dose aspirin 75-100 mg daily, and continue this dual antiplatelet therapy for 12 months as the default strategy. 1, 2

Initial Dosing and Loading

• Loading dose: Administer ticagrelor 180 mg as a single loading dose at presentation 3, 4
• Maintenance dose: Continue ticagrelor 90 mg twice daily thereafter 1, 5
• Aspirin co-administration: Combine with aspirin 75-100 mg daily (never exceed 100 mg daily, as higher aspirin doses reduce ticagrelor's effectiveness) 5, 2, 3

Why Ticagrelor Over Clopidogrel

Ticagrelor or prasugrel are strongly preferred over clopidogrel as first-line therapy for all ACS patients. 1, 2 The 2025 ACC/AHA guidelines explicitly recommend ticagrelor or prasugrel in preference to clopidogrel for ACS patients undergoing PCI. 1 This recommendation is based on superior efficacy in reducing major adverse cardiovascular events and mortality. 6, 4

• Ticagrelor provides faster onset of action (within 30 minutes vs. 2 hours for clopidogrel) and greater platelet inhibition (high on-treatment residual platelet reactivity of ~3% vs. 30-40% with clopidogrel) 6
• If the patient was pre-treated with clopidogrel, discontinue it when starting ticagrelor 3

Standard Duration: 12 Months of DAPT

The default duration is 12 months for all ACS patients who are not at high bleeding risk, regardless of ACS type (STEMI vs. NSTEMI), stent type, or completeness of revascularization. 1, 2, 3

• This applies to both invasively managed patients (with PCI) and those managed medically 1, 2
• For patients treated with fibrinolytic therapy, continue P2Y12 inhibitor for minimum 14 days, ideally 12 months 2

Bleeding Risk Mitigation Strategies

Prescribe a proton pump inhibitor (PPI) with DAPT in all patients—this is a Class I recommendation to reduce gastrointestinal bleeding. 1, 5, 2, 3

Additional bleeding reduction strategies include:

• Use radial artery access over femoral access during PCI when performed by an experienced operator 2, 3
• Maintain aspirin at 75-100 mg daily (not higher doses) when combined with ticagrelor 5, 2, 3

De-escalation Options After Initial Period

For patients who have tolerated DAPT without bleeding complications:

• After ≥1 month of DAPT: Transition to ticagrelor monotherapy (discontinue aspirin) is recommended as a bleeding reduction strategy 1, 5, 3
• For patients requiring long-term anticoagulation: Discontinue aspirin 1-4 weeks after PCI and continue P2Y12 inhibitor (preferably switch to clopidogrel, not ticagrelor) 1, 3

High Bleeding Risk Patients

• If bleeding risk is high (defined as ≥4% annual risk of serious bleeding or ≥1% risk of intracranial hemorrhage), shortened DAPT duration of 3-6 months may be reasonable 2, 6
• High-risk features include: age ≥65 years, low BMI (<18.5), diabetes, prior bleeding, or concurrent oral anticoagulation 6

Critical Pitfalls to Avoid

Never discontinue DAPT prematurely, especially within the first month after stent placement—this dramatically increases risk of stent thrombosis, myocardial infarction, and death. 5, 2, 3

• Never discharge on ticagrelor monotherapy immediately after PCI—DAPT is mandatory during the first month (minimum) to 3 months after stent placement 5
• Never fail to prescribe a PPI with DAPT—this simple intervention significantly reduces GI bleeding 5, 2, 3
• Never use clopidogrel as first-line therapy when ticagrelor or prasugrel are available and not contraindicated 5, 2, 3
• Never administer prasugrel to patients with prior stroke or TIA (contraindicated due to increased cerebrovascular bleeding risk) 2, 6

Perioperative Management

• Continue aspirin perioperatively if bleeding risk allows 2, 3
• Do not discontinue DAPT within the first month for elective non-cardiac surgery—the thrombotic risk is highest in the first month after ACS 2
• For patients undergoing CABG, resume P2Y12 inhibitor therapy after surgery to complete 12 months of DAPT 2

Special Scenarios

• Upstream treatment (pre-catheterization): For NSTE-ACS patients scheduled for invasive strategy with angiography >24 hours away, upstream treatment with ticagrelor may be considered to reduce major adverse cardiovascular events 1, 3
• The ATLANTIC study demonstrated that pre-hospital vs. in-hospital ticagrelor administration was safe with no difference in bleeding rates 4